BX795 was initially developed as a PDK1 inhibitor (direct competitive inhibitor IC50 = 11nM for PDK1) and has been shown to be a potent and relatively specific inhibitor of TBK1 and IKK-ε. It blocks the phosphorylation, nuclear translocation, and transcriptional activity of interferon regulatory factor 3. BX795 also is a potent inhibitor of cell growth of multiple cancer cell lines with IC50 values ranging from submicromolar amounts (0.368 µM to greater than 450 µM).
Product Details
Alternative Name: | N-[3-[[5-iodo-4-[3-(thiophene-2-carbonylamino)propylamino]pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide |
|
Formula: | C23H26IN7O2S |
|
MW: | 591.5 |
|
CAS: | 702675-74-9 |
|
Purity: | ≥97% (HPLC) |
|
Identity: | Determined by NMR. |
|
Appearance: | White to off-white powder. |
|
Solubility: | Soluble in DMSO (80mg/ml). |
|
Shipping: | Ambient Temperature |
|
Short Term Storage: | +4°C |
|
Long Term Storage: | -20°C |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
RalA and RalB relocalization to depolarized mitochondria depends on clathrin-mediated endocytosis and facilitates TBK1 activation: S.R. Pollock, et al.; PLoS One
14, e0214764 (2019),
Abstract;
Full Text